Patient and Tumor Characteristics According to Percentage of Activated CTLs for ALK Positive ALCL Cases
| Case . | Dod . | Surv* . | CTLs . | Tumor . | Age‡ . | Stage . | B-sx . | Therapy . | CR . | Rel . | AW . | IPI . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GrB† . | TIA-1† . | GrB† . | CD8 . | |||||||||||
| ≥15% Activated CTLs | ||||||||||||||
| 30 | − | 15 | 302-153 | 49 | 86 | − | 23 | 2 | + | PC | + | − | + | L |
| 31 | − | 21 | 62 | 64 | 30 | − | 52 | 1 | − | PC | + | − | + | L |
| 32 | − | 34 | 332-153 | 34 | 30 | − | 69 | 1 | − | PC | + | − | + | L |
| 33 | − | 46 | 29 | 32 | 60 | − | 23 | 2 | − | PC + R | + | − | + | L |
| 34 | − | 71 | 24 | 62 | 47 | − | 2 | 1 | + | PC | + | − | + | L |
| <15% Activated CTLs | ||||||||||||||
| 35 | − | 9 | 9 | 24 | 10 | − | 33 | 1 | − | PC + R | + | − | + | L |
| 36 | − | 27 | 142-153 | 28 | 30 | − | 8 | 3 | − | PC | + | − | + | L |
| 37 | − | 33 | 5 | 29 | 0 | − | 14 | 2 | − | PC | + | − | + | LI |
| 38 | − | 36 | 142-153 | 29 | 30 | − | 25 | 4 | + | PC | + | − | + | LI |
| 39 | − | 51 | 12 | 29 | 30 | − | 64 | 2 | − | PC | + | − | + | L |
| 40 | − | 75 | 1 | 9 | 0 | − | 35 | 1 | − | PC + R | + | − | + | L |
| 41 | − | 106 | 2 | 15 | 1 | − | 19 | 2 | + | PC | + | − | + | L |
| 42 | − | 125 | 12 | 62 | 7 | − | 19 | 2 | + | PC + R | + | + | + | L |
| Case . | Dod . | Surv* . | CTLs . | Tumor . | Age‡ . | Stage . | B-sx . | Therapy . | CR . | Rel . | AW . | IPI . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GrB† . | TIA-1† . | GrB† . | CD8 . | |||||||||||
| ≥15% Activated CTLs | ||||||||||||||
| 30 | − | 15 | 302-153 | 49 | 86 | − | 23 | 2 | + | PC | + | − | + | L |
| 31 | − | 21 | 62 | 64 | 30 | − | 52 | 1 | − | PC | + | − | + | L |
| 32 | − | 34 | 332-153 | 34 | 30 | − | 69 | 1 | − | PC | + | − | + | L |
| 33 | − | 46 | 29 | 32 | 60 | − | 23 | 2 | − | PC + R | + | − | + | L |
| 34 | − | 71 | 24 | 62 | 47 | − | 2 | 1 | + | PC | + | − | + | L |
| <15% Activated CTLs | ||||||||||||||
| 35 | − | 9 | 9 | 24 | 10 | − | 33 | 1 | − | PC + R | + | − | + | L |
| 36 | − | 27 | 142-153 | 28 | 30 | − | 8 | 3 | − | PC | + | − | + | L |
| 37 | − | 33 | 5 | 29 | 0 | − | 14 | 2 | − | PC | + | − | + | LI |
| 38 | − | 36 | 142-153 | 29 | 30 | − | 25 | 4 | + | PC | + | − | + | LI |
| 39 | − | 51 | 12 | 29 | 30 | − | 64 | 2 | − | PC | + | − | + | L |
| 40 | − | 75 | 1 | 9 | 0 | − | 35 | 1 | − | PC + R | + | − | + | L |
| 41 | − | 106 | 2 | 15 | 1 | − | 19 | 2 | + | PC | + | − | + | L |
| 42 | − | 125 | 12 | 62 | 7 | − | 19 | 2 | + | PC + R | + | + | + | L |
Abbreviations: Dod, died of disease; Surv, survival; CTLs, cytotoxic T lymphocytes; GrB, granzyme B; TIA, T-cell intracytoplasmic antigen; B-sx, B symptoms; CR, complete remission; Rel, relapse; AW, alive and well (without disease); IPI, International Prognostic Index; PC, polychemotherapy (CHOP regimens or variants); R, radiotherapy; L, low risk; LI, low-intermediate risk; HI, high-intermediate risk; H, high risk.
Survival expressed in months.
GrB and TIA-1 expressed in percentages as quantified by Q-Podit.
Age expressed in years.
Double staining for CD8 and GrB was used as an aid in quantification.